This statement sets out the JCVI’s advice on extending the UK COVID-19 vaccination programme to offer booster doses to adults aged 18 to 39 years and second doses to children and young people aged 12 to 15 years.

According to NICE draft guidance, clinical trial evidence suggests romosozumab followed by alendronic acid is more effective at reducing the risk of fractures than alendronic acid alone. But there is uncertainty because the population in the clinical trial is different to the proposed population.

According to NICE, evidence on the safety and efficacy of the procedure is adequate to support its use provided that standard arrangements are in place for clinical governance, consent and audit. 

The recommendations are part of WHO’s updated living guidance for clinical management of COVID-19.

Risdiplam is recommended in NICE draft guidance as part of a managed access agreement.

Belimumab is the only medicine specifically licensed for treating systemic lupus erythematosus.